PMID- 37565458
OWN - NLM
STAT- MEDLINE
DCOM- 20230906
LR  - 20230906
IS  - 1523-5378 (Electronic)
IS  - 1083-4389 (Linking)
VI  - 28
IP  - 5
DP  - 2023 Oct
TI  - Efficacy and safety of vonoprazan-based dual therapy and esomeprazole-based dual 
      therapy in eradicating primary Helicobacter pylori infection: A propensity score 
      matching analysis.
PG  - e13003
LID - 10.1111/hel.13003 [doi]
AB  - BACKGROUND: According to the Maastricht VI/Florence consensus report, 
      potassium-competitive acid blockers (P-CAB) may improve Helicobacter pylori 
      eradication treatment. MATERIALS AND METHODS: A total of 213 H. pylori 
      treatment-naive patients aged between 18 and 70 years were treated with two 
      regimens. The two regimens are VDT: 20 mg vonoprazan twice a day and 1 g 
      amoxicillin three times daily and EDT: 20 mg esomeprazole four times a day and 
      750 mg amoxicillin four times daily. (13) C-urea breath tests were used to 
      evaluate eradication rate 4-6 weeks after treatment. Based on propensity score 
      matching (PSM), this retrospective study analyzed the eradication rates, adverse 
      events (AEs), compliance, and antibiotic resistance rates in VDT and EDT groups. 
      RESULTS: On intention-to-treat (ITT) analysis, the eradication rate in VDT group 
      (89.0%; 95% CI 81.7-96.3) was non-inferior to that in EDT group (87.7%; 95% CI 
      80.1-95.3; p = 0.796). The corresponding per-protocol (PP) eradication rates were 
      94.1% (95% CI 88.4-99.8) and 92.8% (95% CI 86.7-98.9; p = 1.000), respectively. 
      There were no significant between-group differences with respect to compliance or 
      incidence of AEs. CONCLUSIONS: The efficacy and safety of 14-day VDT and EDT were 
      comparable. Therefore, 14-day VDT or EDT may be recommended for the first-line 
      treatment of H. pylori infection.
CI  - (c) 2023 John Wiley & Sons Ltd.
FAU - Su, Na-Yun
AU  - Su NY
AUID- ORCID: 0000-0002-1526-0425
AD  - Department of Gastroenterology, Chongqing Key Laboratory of Digestive 
      Malignancies, Daping Hospital, Army Medical University, Third Military Medical 
      University, Chongqing, China.
FAU - Shi, Qing
AU  - Shi Q
AD  - Department of Gastroenterology, Chongqing Key Laboratory of Digestive 
      Malignancies, Daping Hospital, Army Medical University, Third Military Medical 
      University, Chongqing, China.
FAU - Mei, Hao
AU  - Mei H
AD  - Department of Gastroenterology, Chongqing Key Laboratory of Digestive 
      Malignancies, Daping Hospital, Army Medical University, Third Military Medical 
      University, Chongqing, China.
FAU - Hu, Jie
AU  - Hu J
AD  - Department of Gastroenterology, Chongqing Key Laboratory of Digestive 
      Malignancies, Daping Hospital, Army Medical University, Third Military Medical 
      University, Chongqing, China.
FAU - Liu, Yu-Xiang
AU  - Liu YX
AD  - Department of Gastroenterology, Chongqing Key Laboratory of Digestive 
      Malignancies, Daping Hospital, Army Medical University, Third Military Medical 
      University, Chongqing, China.
FAU - Liu, Han-Ning
AU  - Liu HN
AD  - Department of Gastroenterology, Chongqing Key Laboratory of Digestive 
      Malignancies, Daping Hospital, Army Medical University, Third Military Medical 
      University, Chongqing, China.
FAU - Liu, Heng-Qi
AU  - Liu HQ
AD  - Department of Gastroenterology, Chongqing Key Laboratory of Digestive 
      Malignancies, Daping Hospital, Army Medical University, Third Military Medical 
      University, Chongqing, China.
FAU - Guo, Yan
AU  - Guo Y
AD  - Department of Gastroenterology, Chongqing Key Laboratory of Digestive 
      Malignancies, Daping Hospital, Army Medical University, Third Military Medical 
      University, Chongqing, China.
FAU - Wang, Xing-Wei
AU  - Wang XW
AD  - Department of Gastroenterology, Chongqing Key Laboratory of Digestive 
      Malignancies, Daping Hospital, Army Medical University, Third Military Medical 
      University, Chongqing, China.
FAU - Lan, Chun-Hui
AU  - Lan CH
AUID- ORCID: 0000-0002-9232-7910
AD  - Department of Gastroenterology, Chongqing Key Laboratory of Digestive 
      Malignancies, Daping Hospital, Army Medical University, Third Military Medical 
      University, Chongqing, China.
LA  - eng
GR  - NO.82072253/National Natural Science Foundation of China/
GR  - cstc2021jcyj-msxmX0451/Natural Science Foundation Project of Chongqing, Chongqing 
      Science and Technology Commission/
PT  - Journal Article
DEP - 20230810
PL  - England
TA  - Helicobacter
JT  - Helicobacter
JID - 9605411
RN  - N3PA6559FT (Esomeprazole)
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 
      (1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine)
RN  - 0 (Proton Pump Inhibitors)
RN  - 804826J2HU (Amoxicillin)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Humans
MH  - Adolescent
MH  - Young Adult
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - *Helicobacter Infections/drug therapy
MH  - Esomeprazole/therapeutic use
MH  - *Helicobacter pylori
MH  - Anti-Bacterial Agents/adverse effects
MH  - Retrospective Studies
MH  - Propensity Score
MH  - Proton Pump Inhibitors/adverse effects
MH  - Amoxicillin/therapeutic use
MH  - Drug Therapy, Combination
MH  - Treatment Outcome
MH  - Clarithromycin/therapeutic use
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - eradication therapy
OT  - high-dose dual therapy
OT  - risk factors
OT  - vonoprazan
EDAT- 2023/08/11 06:42
MHDA- 2023/09/06 06:42
CRDT- 2023/08/11 05:53
PHST- 2023/05/25 00:00 [revised]
PHST- 2023/03/16 00:00 [received]
PHST- 2023/06/14 00:00 [accepted]
PHST- 2023/09/06 06:42 [medline]
PHST- 2023/08/11 06:42 [pubmed]
PHST- 2023/08/11 05:53 [entrez]
AID - 10.1111/hel.13003 [doi]
PST - ppublish
SO  - Helicobacter. 2023 Oct;28(5):e13003. doi: 10.1111/hel.13003. Epub 2023 Aug 10.